Novo Nordisk signs up-to-$2.1 billion partnership with Boston startup Vivtex to develop new weight-loss pills

A new Boston collaboration targets oral alternatives to injectable obesity and diabetes medicines

Novo Nordisk, the Danish drugmaker behind Ozempic and Wegovy, has signed a development deal with Boston startup Vivtex aimed at creating “next-generation” pill-form medicines for obesity and diabetes. The agreement could be worth up to $2.1 billion to Vivtex if research, development, and commercial milestones are met, in addition to an upfront payment and potential royalties on any products that reach the market.

The partnership adds momentum to an increasingly competitive push toward oral therapies in the fast-growing class of GLP-1–based treatments and related metabolic drugs, where demand has surged and manufacturers are seeking products that are easier to take, simpler to distribute, and more scalable than injectables.

Who Vivtex is and what Novo Nordisk is buying

Vivtex was founded roughly eight years ago as a spinout involving three Massachusetts Institute of Technology scientists, including Robert Langer, a longtime MIT professor and cofounder of Moderna, along with Giovanni Traverso and Thomas von Erlach. Von Erlach is Vivtex’s chief executive. The company is based in Dorchester.

Vivtex focuses on identifying drug candidates suitable for oral delivery—an approach that is technically challenging for many compounds that are readily delivered by injection. Its platform combines high-throughput screening and computational methods to evaluate candidates designed to be absorbed through the gastrointestinal tract. The company has also described work using lab systems intended to model intestinal function for rapid testing of potential oral therapies.

How the deal fits the broader market for weight-loss drugs

Novo Nordisk and Eli Lilly are the two dominant players in the modern obesity-drug market, with both companies expanding beyond first-generation products and competing on efficacy, convenience, and access. Novo Nordisk recently began U.S. rollout of an oral form of Wegovy following federal approval in December 2025, positioning it as an alternative for patients who prefer not to use injections.

The Vivtex agreement arrives amid intensified pressure for innovation and differentiation. Lilly’s tirzepatide-based products have posted strong clinical results, and the company is also pursuing oral options in development.

What comes next

Under the partnership, Vivtex and Novo Nordisk plan to work on oral candidates that could include additional GLP-1–based drugs or therapies in other metabolic medicine categories. Financial terms beyond the milestone ceiling, including the size of the upfront payment, were not disclosed.

Vivtex has also reported multiple other pharmaceutical collaborations, underscoring a broader industry strategy: pairing large drugmakers’ development and commercialization capacity with specialized platforms designed to accelerate discovery of orally deliverable treatments.

• Deal structure: upfront payment, milestones up to $2.1 billion, plus royalties if products are commercialized
• Therapeutic focus: obesity and diabetes; emphasis on oral delivery
• Strategic context: accelerating competition to produce effective, scalable pill-form alternatives to injections

The collaboration reflects a wider shift in obesity drug development toward convenience and manufacturability, as companies seek to expand treatment adoption beyond injection-based regimens.